Literature DB >> 23881601

Modeling the absorbed dose to the common carotid arteries following radioiodine treatment of benign thyroid disease.

Jeppe Lerche la Cour1, Per Hedemann-Jensen, Jens Søgaard-Hansen, Birte Nygaard, Lars Thorbjørn Jensen.   

Abstract

INTRODUCTION: External fractionated radiotherapy of cancer increases the risk of cardio- and cerebrovascular events, but less attention has been paid to the potential side effects on the arteries following internal radiotherapy with radioactive iodine (RAI), i.e. 131-iodine. About 279 per million citizens in the western countries are treated each year with RAI for benign thyroid disorders (about 140,000 a year in the EU), stressing that it is of clinical importance to be aware of even rare radiation-induced side effects. In order to induce or accelerate atherosclerosis, the dose to the carotid arteries has to exceed 2 Gy which is the known lower limit of ionizing radiation to affect the endothelial cells and thereby to induce atherosclerosis.
OBJECTIVE: To estimate the radiation dose to the carotid arteries following RAI therapy of benign thyroid disorders.
METHODS: Assuming that the lobes of the thyroid gland are ellipsoid, that the carotid artery runs through a part of the lobes, that there is a homogeneous distribution of RAI in the lobes, and that the 24 h RAI uptake in the thyroid is 35 % of the (131)I orally administrated, we used integrated modules for bioassay analysis and Monte Carlo simulations to calculate the dose in Gy/GBq of administrated RAI.
RESULTS: The average radiation dose along the arteries is 4-55 Gy/GBq of the (131)I orally administrated with a maximum dose of approximately 25-85 Gy/GBq. The maximum absorbed dose rate to the artery is 4.2 Gy/day per GBq (131)I orally administrated.
CONCLUSION: The calculated radiation dose to the carotid arteries after RAI therapy of benign thyroid disorder clearly exceeds the 2 Gy known to affect the endothelial cells and properly induce atherosclerosis. This simulation indicates a relation between the deposited dose in the arteries following RAI treatment and an increased risk of atherosclerosis and subsequent cerebrovascular events such as stroke.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881601     DOI: 10.1007/s12149-013-0756-y

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  4 in total

1.  Risk Factors for Cardiovascular Disease Among Thyroid Cancer Survivors: Findings From the Utah Cancer Survivors Study.

Authors:  Jihye Park; Brenna E Blackburn; Patricia A Ganz; Kerry Rowe; John Snyder; Yuan Wan; Vikrant Deshmukh; Michael Newman; Alison Fraser; Ken Smith; Kim Herget; Anne C Kirchhoff; Dev Abraham; Jaewhan Kim; Marcus Monroe; Mia Hashibe
Journal:  J Clin Endocrinol Metab       Date:  2018-07-01       Impact factor: 5.958

2.  Cardiovascular Effects of Cumulative Doses of Radioiodine in Differentiated Thyroid Cancer Patients with Type 2 Diabetes Mellitus.

Authors:  Adina Elena Stanciu; Marcel Marian Stanciu; Anca Zamfirescu; Dan Cristian Gheorghe
Journal:  Cancers (Basel)       Date:  2022-05-10       Impact factor: 6.575

3.  Radioiodine Therapy Does Not Change the Atherosclerotic Burden of the Carotid Arteries.

Authors:  Jeppe Lerche la Cour; Ulrik Bjørn Andersen; Christian Hjort Sørensen; Birte Nygaard; Lars Thorbjørn Jensen
Journal:  Thyroid       Date:  2016-05-20       Impact factor: 6.568

4.  Effects of radioactive iodine treatment on cardiovascular disease in thyroid cancer patients: a nationwide cohort study.

Authors:  Kyeong Jin Kim; Ji Eun Song; Ji Yoon Kim; Jae Hyun Bae; Nam Hoon Kim; Hye Jin Yoo; Hee Young Kim; Ji A Seo; Nan Hee Kim; Juneyoung Lee; Kyung Mook Choi; Sei Hyun Baik; Sin Gon Kim
Journal:  Ann Transl Med       Date:  2020-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.